The U.S. direct-to-consumer (DTC) genetic testing market is anticipated to observe remarkable growth on account of intensifying popularity of DTC genetic testing kits. These testing kits can easily monitor a patient’s distinctive molecular profile and genetics.

In the U.S., DTC genetic testing is considered to be cost-effective method for collecting medical information about patient health. Proliferating adoption of advanced DTC genetic tests by U.S. consumers could broaden the business horizon for the DTC genetic testing kit manufacturers. Global Market Insights, Inc., forecasts that the U.S. direct-to-consumer genetic testing market might reach USD 850 million by the year 2025.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/4368  

DTC genetic tests facilitate the need for personalized treatment for patients that suffer from melanoma, breast cancer and various other genetic diseases. Growing prevalence of these diseases could create a significant demand for direct-to-consumer genetic tests in the United States.

Personalized DTC genetic testing services are gaining immense traction owing to its user-friendly nature and flexible characteristics. These testing kits allow patients to conduct testing at their home. According to MIT’s Technology Review, nearly 8% of the US population, which comes down to 26 million people, conducted in-home DNA tests in 2019, figures that are predicted to go over 100 million within the next 24 months. 

Speculating increasing demand, industry participants are focusing on developing technologically advanced testing solutions. Citing an instance, 23andMe developed a DTC test that uses genotype testing solutions to deliver accurate data on carrier status, health, and behavioral attributes for analyzing drug interactions. 

Predictive testing, also known as presymptomatic testing, helps in detecting gene mutations that are associated with disorders that occur after birth or later in life. Estimates suggest that the segment could record a compound annual growth rate of more than 16% within the predicted timeframe.

Request for customization @ https://www.decresearch.com/roc/4368

Rising emergence of new and advanced platforms that efficiently perform genome analysis coupled with growing prevalence of genetic or contagious diseases might positively boost the adoption of predictive direct-to-genetic testing equipment in the U.S. 

Companies operating in the U.S. DTC genetic testing industry are primarily focusing on adopting several strategic initiatives like mergers, acquisitions, geographical expansions and product launches to expand their consumer base and market share. Taking September 2020 for instance, Vibrent Health, a health research platform developer, revealed that it has received a $39 million infusion from the National Institutes of Health. The investment aims on extending the public research organization's All of Us Research initiative.

Partial Chapter of the Table of Content

Chapter 2. Executive Summary

2.1.    U.S. Direct-To-Consumer (DTC) genetic Testing industry 360⁰ synopsis, 2014 - 2025

Chapter 3. U.S. Direct-To-Consumer (DTC) Genetic Testing Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2014 - 2025

3.3. Industry impact forces

3.3.1.  Growth drivers

3.3.1.1.    Rising public awareness regarding DTC genetic tests

3.3.1.2.    Increasing demand for personalized DTC genetic services

3.3.1.3.    Rising incidences of genetic disorders

3.3.2.  Industry pitfalls and challenges

3.3.2.1.    Defects in the DTC testing

3.4. Growth potential analysis

3.4.1.  By test type

3.4.2.  By technology

3.5. Regulatory landscape

3.6. Porter’s analysis

3.7. Competitive landscape, 2018

3.7.1.  Strategy dashboard

3.8. PESTEL analysis

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/us-direct-to-consumer-genetic-testing-market